Paul Fackler

Dr. Fackler joined Alvogen in 2018 and directs both their clinical and non-clinical studies. Prior to Alvogen, he was at Merck Research Laboratories from 2010 to 2018 managing a clinical group to support development of second-generation products such as new fixed dose combinations, products with improved PK profiles, and those with new delivery routes. He also worked at Teva Pharmaceuticals as Vice President Generic R&D, 1998 to 2010, Springborn Laboratories, and Johnson Matthey. He has served on the FDA Advisory Committee for Clinical Pharmacology and has been on two USP expert committees.